Role of GABAB Receptor of the Pedunculopontine Tegmental (PPT) Nucleus on Cardiovascular Responses in Normotensive Rats
Publish place: Third International Nervous System Inflammatory Conference and Third Student Neuroscience Festival
Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 444
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
NIMED03_083
تاریخ نمایه سازی: 7 آبان 1398
Abstract:
The Pedunculopontine Tegmental (PPT) is a mesencephalic nucleus that involved in numerous functions including movements, sleep, pain andalso respiratory and cardiovascular regulation. This nucleus has many neurotransmitters including gamma aminobutyric acid (GABA). In our previous study, the effect of GABAA receptor of the PPT on cardiovascular function was determined. In this study the role of theGABAB receptor of this nucleus on cardiovascular response has been studied. Materials and Methods: In this study animals were randomly divided in following groups: 1) Control and 2-4) Baclofen (as a GABAB agonist with 3 doses; 0.5, 1 and 2.5 nm), 5-7) Phaclofen (as a GABAB antagonist with 3 doses; 0.5, 1 and 2.5 nm). To measure the cardiovascular parameters, the femoral artery was cannulated and connected to pressure transducer and by means of a power lab device the mean arterial pressure (MAP), systolic blood pressure (SBP) and heart rate (HR) were recorded. The drugs were microinjected into the PPT nucleus using stereotactic device. Changes of SBP, MAP and HR before andafter injection of drugs were calculated and compared with the control group (one-way ANOVA with post hoc tukey’s). Results: Microinjection of baclofen and phaclofen at 0.5 and 1 nm doses did not significantly change the MAP, SBP and HR. However, dose 2.5 baclofen (GABAB agonist), significantly reduced HR (P<0.05) and had not significant effect on SBP and MAP. The dose 2.5 phaclofen (GABAB antagonist) alsosignificantly increased SBP (P<0.05) and HR (P<0.01) but had not significant effect on MAP. Conclusions: The results show that the GABAB receptor agonist in higher dose has inhibitory effects on cardiovascular parameters, especially on HR.
Authors
Mohammad Hosein Khajavi Rad
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Hosein Pasandi
Deartment of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Mohammad Naser Shafei
Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abolfazl Khajavi Rad
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran